IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Invicta Diagnostic IPO is a book build IPO listing on NSE EMERGE exchange. The company is based in Mumbai and caters to Healthcare - Hospitals And Clinic sector. Socradamus Capital Private is the merchant banker of Invicta Diagnostic IPO. It is a SME UPCOMING IPO which filed its Draft Red Herring Prospectus (DRHP) on 2nd August 2024.
Invicta Diagnostic IPO posted revenues of Rs 8.37 crores and PAT of Rs 2.04 crores in FY25 on annualised basis.Financial results of Invicta Diagnostic IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Invicta Diagnostic IPO PAT Margin is 28.71%, ROCE (Return on Capital Employed) is 21.98% as per latest financial. The below table shows Invicta Diagnostic IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Invicta Diagnostic IPO is Rs [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Invicta Diagnostic IPO prospectus highlights an Return on Equity (ROE) of 15%, Return on Assets (ROA) of 12%, and an EBITDA Margin of 18%, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Invicta Diagnostic IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Invicta Diagnostic IPO is ₹[●] Cr, based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Invicta Diagnostic IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Invicta Diagnostic IPO reported revenue of ₹8.37 Cr in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Invicta Diagnostic IPO provide insights into sales growth, market demand, and business scalability.
Invicta Diagnostic recorded an EBITDA of ₹ 3.87 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Invicta Diagnostic Profit After Tax (PAT) is ₹2.40 Cr, reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 8.36 Cr.
EBITDA Margin:
46.29
%
Net Worth: ₹ 9.73 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: 0.64 times
Invicta Diagnostic operates in Healthcare - Hospitals And Clinic and . The Issue is listed on NSE EMERGE in Apr, 2025. Invicta Diagnostic IPO size was with Issue price of .
Merchant Banker(s) of Invicta Diagnostic IPO: Socradamus Capital Private Limited
Invicta Diagnostic IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Invicta Diagnostic IPO listed at a listing price of against the offer price of .
The current market price of Invicta Diagnostic is .
Why Us?
